199 related articles for article (PubMed ID: 25242871)
1. Flavocoxid, a nutraceutical approach to blunt inflammatory conditions.
Bitto A; Squadrito F; Irrera N; Pizzino G; Pallio G; Mecchio A; Galfo F; Altavilla D
Mediators Inflamm; 2014; 2014():790851. PubMed ID: 25242871
[TBL] [Abstract][Full Text] [Related]
2. A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation.
Burnett BP; Jia Q; Zhao Y; Levy RM
J Med Food; 2007 Sep; 10(3):442-51. PubMed ID: 17887937
[TBL] [Abstract][Full Text] [Related]
3. Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages.
Altavilla D; Squadrito F; Bitto A; Polito F; Burnett BP; Di Stefano V; Minutoli L
Br J Pharmacol; 2009 Aug; 157(8):1410-8. PubMed ID: 19681869
[TBL] [Abstract][Full Text] [Related]
4. Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study.
Levy RM; Saikovsky R; Shmidt E; Khokhlov A; Burnett BP
Nutr Res; 2009 May; 29(5):298-304. PubMed ID: 19555810
[TBL] [Abstract][Full Text] [Related]
5. Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant.
Burnett BP; Bitto A; Altavilla D; Squadrito F; Levy RM; Pillai L
Mediators Inflamm; 2011; 2011():385780. PubMed ID: 21765617
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee.
Levy RM; Khokhlov A; Kopenkin S; Bart B; Ermolova T; Kantemirova R; Mazurov V; Bell M; Caldron P; Pillai L; Burnett BP
Adv Ther; 2010 Oct; 27(10):731-42. PubMed ID: 20845002
[TBL] [Abstract][Full Text] [Related]
7. Using the medical food flavocoxid [corrected] in managing osteoarthritis.
Gottlieb D; Kuritzky L
J Pain Palliat Care Pharmacother; 2011; 25(1):49-54. PubMed ID: 21426218
[TBL] [Abstract][Full Text] [Related]
8. Antioxidant and anti-inflammatory effects of flavocoxid in high-cholesterol-fed rabbits.
El-Sheakh AR; Ghoneim HA; Suddek GM; Ammar el-SM
Naunyn Schmiedebergs Arch Pharmacol; 2015 Dec; 388(12):1333-44. PubMed ID: 26341793
[TBL] [Abstract][Full Text] [Related]
9. The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis.
Morgan SL; Baggott JE; Moreland L; Desmond R; Kendrach AC
J Med Food; 2009 Oct; 12(5):1143-8. PubMed ID: 19857081
[TBL] [Abstract][Full Text] [Related]
10. Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
Pallio G; Bitto A; Pizzino G; Galfo F; Irrera N; Minutoli L; Arcoraci V; Squadrito G; Macrì A; Squadrito F; Altavilla D
Eur J Pharmacol; 2016 Oct; 789():152-162. PubMed ID: 27450484
[TBL] [Abstract][Full Text] [Related]
11. Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia.
Altavilla D; Minutoli L; Polito F; Irrera N; Arena S; Magno C; Rinaldi M; Burnett BP; Squadrito F; Bitto A
Br J Pharmacol; 2012 Sep; 167(1):95-108. PubMed ID: 22471974
[TBL] [Abstract][Full Text] [Related]
12. Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis.
Polito F; Bitto A; Irrera N; Squadrito F; Fazzari C; Minutoli L; Altavilla D
Br J Pharmacol; 2010 Nov; 161(5):1002-11. PubMed ID: 20977452
[TBL] [Abstract][Full Text] [Related]
13. GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin.
Pillai L; Burnett BP; Levy RM;
Curr Med Res Opin; 2010 May; 26(5):1055-63. PubMed ID: 20225990
[TBL] [Abstract][Full Text] [Related]
14. Cost analysis of flavocoxid compared to naproxen for management of mild to moderate OA.
Walton SM; Schumock GT; McLain DA
Curr Med Res Opin; 2010 Sep; 26(9):2253-61. PubMed ID: 20690891
[TBL] [Abstract][Full Text] [Related]
15. Comparative safety of flavocoxid vs prescription NSAIDs among osteoarthritis patients.
Curtis JR; Owensby JK; Xie F
Osteoarthritis Cartilage; 2020 Jul; 28(7):917-923. PubMed ID: 32305527
[TBL] [Abstract][Full Text] [Related]
16. Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone.
Messina S; Bitto A; Aguennouz M; Mazzeo A; Migliorato A; Polito F; Irrera N; Altavilla D; Vita GL; Russo M; Naro A; De Pasquale MG; Rizzuto E; Musarò A; Squadrito F; Vita G
Exp Neurol; 2009 Dec; 220(2):349-58. PubMed ID: 19786019
[TBL] [Abstract][Full Text] [Related]
17. 90-day oral toxicity study of UP446, a combination of defined extracts of Scutellaria baicalensis and Acacia catechu, in rats.
Yimam M; Zhao Y; Ma W; Jia Q; Do SG; Shin JH
Food Chem Toxicol; 2010 May; 48(5):1202-9. PubMed ID: 20171255
[TBL] [Abstract][Full Text] [Related]
18. Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series.
Chalasani N; Vuppalanchi R; Navarro V; Fontana R; Bonkovsky H; Barnhart H; Kleiner DE; Hoofnagle JH
Ann Intern Med; 2012 Jun; 156(12):857-60, W297-300. PubMed ID: 22711078
[TBL] [Abstract][Full Text] [Related]
19. Reduction of oxidative stress blunts the NLRP3 inflammatory cascade in LPS stimulated human gingival fibroblasts and oral mucosal epithelial cells.
Picciolo G; Mannino F; Irrera N; Minutoli L; Altavilla D; Vaccaro M; Oteri G; Squadrito F; Pallio G
Biomed Pharmacother; 2022 Feb; 146():112525. PubMed ID: 34906776
[TBL] [Abstract][Full Text] [Related]
20. The natural dual cyclooxygenase and 5-lipoxygenase inhibitor flavocoxid is protective in EAE through effects on Th1/Th17 differentiation and macrophage/microglia activation.
Kong W; Hooper KM; Ganea D
Brain Behav Immun; 2016 Mar; 53():59-71. PubMed ID: 26541818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
